Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Desvenlafaxine SR in Japanese Adults with MDD
NCT00831415Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2009
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of desvenlafaxine in major depressive disorder (MDD), sponsored by Pfizer. Primary endpoints: Change From Baseline in Hamilton Psychiatric Scale for Depression-17 Item Score at Day 308 and Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) at Day 329. Started Mar 2009; status: completed.
02
Drugs
desvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00831415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00831415.